Diagnostic and Prognostic Implications of FGFR3(high)/Ki67(high) Papillary Bladder Cancers by Geelvink, Mirja et al.
 International Journal of 
Molecular Sciences
Article
Diagnostic and Prognostic Implications of
FGFR3high/Ki67high Papillary Bladder Cancers
Mirja Geelvink 1, Armin Babmorad 1, Angela Maurer 1, Robert Stöhr 2, Tobias Grimm 3 ID ,
Christian Bach 4, Ruth Knuechel 1, Michael Rose 1,† and Nadine T. Gaisa 1,*,†
1 Institute of Pathology, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany;
mirja.geelvink@rwth-aachen.de (M.G.); armin.babmorad@rwth-aachen.de (A.B.);
amaurer@ukaachen.de (A.M.); rknuechel-clarke@ukaachen.de (R.K.); mrose@ukaachen.de (M.R.)
2 Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University
Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Robert.Stoehr@uk-erlangen.de
3 Department of Urology, Ludwig Maximilian University Munich, 81377 Munich, Germany;
Tobias_Grimm@med.uni-muenchen.de
4 Department of Urology, RWTH Aachen University, 52074 Aachen, Germany; chbach@ukaachen.de
* Correspondence: ngaisa@ukaachen.de; Tel.: +49-241-8036118; Fax: +49-241-8082439
† These authors are contributed equally.
Received: 30 July 2018; Accepted: 24 August 2018; Published: 28 August 2018


Abstract: Prognostic/therapeutic stratification of papillary urothelial cancers is solely based upon
histology, despite activated FGFR3-signaling was found to be associated with low grade tumors and
favorable outcome. However, there are FGFR3-overexpressing tumors showing high proliferation—a
paradox of coexisting favorable and adverse features. Therefore, our study aimed to decipher the
relevance of FGFR3-overexpression/proliferation for histopathological grading and risk stratification.
N = 142 (n = 82 pTa, n = 42 pT1, n = 18 pT2-4) morphologically G1–G3 tumors were analyzed
for immunohistochemical expression of FGFR3 and Ki67. Mutation analysis of FGFR3 and TP53
and FISH for FGFR3 amplification and rearrangement was performed. SPSS 23.0 was used for
statistical analysis. Overall FGFR3high/Ki67high status (n = 58) resulted in a reduced ∆mean
progression-free survival (PFS) (p < 0.01) of 63.92 months, and shorter progression-free survival
(p < 0.01; mean PFS: 55.89 months) in pTa tumors (n = 50). FGFR3mut/TP53mut double mutations led
to a reduced ∆mean PFS (p < 0.01) of 80.30 months in all tumors, and FGFR3mut/TP53mut pTa tumors
presented a dramatically reduced PFS (p < 0.001; mean PFS: 5.00 months). Our results identified
FGFR3high/Ki67high papillary pTa tumors as a subgroup with poor prognosis and encourage
histological grading as high grade tumors. Tumor grading should possibly be augmented by
immunohistochemical stainings and suitable clinical surveillance by endoscopy should be performed.
Keywords: FGFR3; Ki67; TP53; bladder cancer; prognosis
1. Introduction
Bladder cancer is the second most common genitourinary malignancy [1]. At primary diagnosis,
most of the tumors are papillary non-invasive cancers (pTa) which are mostly well differentiated but
show a high rate of recurrence. Those tumors are characterized by certain molecular alterations as
for example FGFR3 activation [2–5]. Up to 30% of all patients have invasive disease at diagnosis.
These tumors frequently derive from flat carcinoma in situ (CIS) of the urothelium (a high grade lesion,
often TP53-mutated) and quickly develop muscle-invasion and metastasis [6,7]. Current prognostic
and therapeutic stratification in urothelial cancers is therefore based on tumor staging and grading at
histological examination. Staging criteria is the depth of invasion defined by the tumor node metastasis
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(TNM)-classification of the Union Internationale Contre le Cancer (UICC) [8]. The tumor grading is
based upon architectural order and nuclear shape features, which have been thoroughly defined as
diagnostic criteria in the 2004 WHO classification of bladder cancer in order to achieve reproducible
and comparable diagnoses worldwide. Low grade (LG) tumors show uniform, slightly enlarged
nuclei in an orderly, polarized architecture, sometimes with a prominent palisading of the basal
layer. Mitotic figures are infrequent [9,10]. High grade (HG) tumors show more pleomorphic nuclei
with multiple mitotic features and various extent of architectural disarray [10]. Based on previous
genetic analyses and clinical observations, it has been proposed that the histological appearance
(grading) of tumors correlates with the underlying genetic alterations, and low grade tumors were
regarded genetically stable, whereas high grade tumors, harboring a high number of genetic alterations,
were considered genetically “unstable” [7]. Proposed prognostic markers in papillary non-invasive
tumors have been the Ki67 labeling index (marker for cell proliferation) and keratin 20 expression
(marker for cell differentiation). Tumors with Ki67≥ 15% were regarded as highly proliferative [11–13]
and aberrant expression of keratin 20 was linked to disease recurrence in pTa tumors [14]. Lately,
Hurst et al. conducted a comprehensive molecular study on n = 141 papillary non-invasive bladder
cancers (low grade, G1 and G2 according to WHO 1973) and found lower overall mutation rates,
but more mutations in chromatin modifying genes than in muscle-invasive bladder cancer, and two
distinct genomic subgroups of tumors (genomic subtype 1 and 2). The majority of tumors with genomic
subtype 1 showed no or only few copy-number alterations. Genomic subtype 2 was characterized
by loss of 9q (including the mTORC1 regulator TSC1), increased Ki67 labeling index, upregulated
mTORC1 signaling (comprising the overrepresentation of genes in processes that are involved in the
unfolded protein response, glycolysis, and cholesterol homeostasis) as well as enrichment for DNA
repair and cell-cycle genes [15]. FGFR3 mutations were not found to be significantly different in both
subgroups (72% vs. 89%) and TP53 mutations were absent [15]. The authors did not show a correlation
of molecular profiles with specific histological features.
However, in routine histological diagnostics, pathologists often see papillary non-invasive tumors
with quite uniform, relatively small nuclei, which give a “crowded” impression, but seem to be of
“low nuclear grade”. Interestingly, Ki67 labeling in these tumors is often enhanced and from this
point of view a reconsideration of a possible “high grade”-biology is implicated. Opposite to the
negative predictive impact of a high Ki67 index, these tumors often show a strong expression of
FGFR3, which indicates an activation of the signaling pathway resulting in cellular proliferation,
but is generally associated with a benign course of disease with higher recurrence rates but less
progression [7]. Being aware of this diagnostic-biological “dilemma”, we delineated in this study the
immunohistochemical and genetic basis of such FGFR3high/Ki67high papillary bladder cancers in order
to reveal their prognostic impact.
2. Results
2.1. Immunohistochemical Combination of Ki67-Index and FGFR3 Levels Defines Worse Patients’ Outcome
Overall, FGFR3 and Ki67 protein expression was analyzed by immunohistochemistry
(Figure 1A–I) in n = 142 primary bladder tumors comprising n = 82 papillary non-invasive tumors (for
cohort characteristics, see Table S1). In this cohort, 87/142 patients (61.3%) showed a high Ki67-index
(≥15% positivity) and 100/142 bladder cancer patients (70.4%) were characterized by strong FGFR3
expression (Tomlinson Score 3) (Figure S1A,C). In papillary non-invasive pTa tumors, 82.9% showed
strong FGFR3 and 54.9% increased Ki67 expression (Figure S1B,D).
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Figure 1. FGFR3 and Ki67 protein expression in papillary non-invasive (pTa) bladder tumors. 
Immunohistochemical staining for FGFR3 and Ki67 protein of representative tumors are shown. (A–
C) pTa low grade (LG) tumor: (A) Hematoxylin and Eosin (HE) staining; (B) strong FGFR3 
immunoreactivity; and (C) only a few cell nuclei are positive for Ki67 expression. (D–F) pTa tumor 
with “crowded low nuclear grade” (pTa?) morphology: (D) HE staining; (E) strong FGFR3 
immunoreactivity; and (F) high nuclear Ki67 protein staining. (G–I) pTa high grade (HG) tumor: (G) 
HE staining; (H) moderate FGFR3 protein expression; and (I) high nuclear Ki67 staining. Scale bar: 
500 µm; original digital magnifications vary from 5× to 7×. 
Next, associations between clinico-pathological characteristics and both FGFR3 and Ki67 protein 
expression were tested. FGFR3 expression and Ki67 index correlated with tumor grading (FGFR3: p 
< 0.001, Ki67: p < 0.001), but only FGFR3 expression was significantly associated with tumor stage 
(FGFR3: p < 0.001) (Tables 1 and 2). No association was found between FGFR3/Ki67 and age at 
diagnosis or gender. 
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(A–C) pTa low grade (LG) tumor: (A) Hematoxylin and Eosin (HE) staining; (B) t
i r ti it ; and (C) only a few cell nuclei are positive for Ki67 expression. (D–F) pTa tumor with
“crowded low nuclear grade” (pTa?) morphology: (D) HE staining; (E) strong FGFR3 immunoreactivity;
and (F) high nuclear Ki67 protein staining. (G–I) pTa high grade (HG) tumor: (G) HE staining;
(H) moderate FGFR3 protein expression; and (I) high nuclear Ki67 staining. Scale bar: 500 µm; original
digital magnifications vary from 5× to 7×.
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Table 1. Clinico-pathological parameters in correlation to FGFR3 protein expression.
FGFR3 Expression a
n 0–2 3 p-Value b Spearman ρ
Parameter:
Age at diagnosis
<70 years 67 20 47
0.946 0.006≥70 years 75 22 53
Gender
female 31 10 21
0.372 0.031male 111 32 79
Histological tumor grade
low grade 49 3 46
<0.001 −0.373high grade 93 39 54
Tumor stage
pTa 82 14 68
<0.001 −0.320pT1–pT4 60 28 32
a Tomlinson score according to [16]; b Fisher’s exact test; Significant p-values are marked in bold face.
Table 2. Clinico-pathological parameters in correlation to Ki67 protein expression.
Ki67 Expression a
n <15% ≥15% p-Value b Spearman ρ
Parameter:
Age at diagnosis
<70 years 67 31 36
0.083 0.146≥70 years 75 24 51
Gender
female 31 14 17
0.408 0.070male 111 41 70
Histological tumor grade
low grade 49 34 15
<0.001 0.457high grade 93 21 72
Tumor stage
pTa 82 37 45
0.069 0.175pT1–pT4 60 18 42
a According to [11]; b Fisher’s exact test; Significant p-values are marked in bold face.
To assess the clinical impact, Kaplan–Meier analyses were performed. FGFR3 expression had no
significant impact on progression-free survival (PFS) (Figure 2A). In contrast, enhanced Ki67 expression
(≥15%) significantly predicted shorter progression-free survival (∆mean PFS: 2.71 months, p = 0.043).
Finally, we aimed to decipher the potential prognostic impact of combined FGFR3 expression and Ki67
index: FGFR3high/Ki67high status was found in n = 58 cases. A combined analysis of FGFR3/Ki67
positivity (Figure 2C and Figure S2A) resulted in a reduced ∆mean PFS (p < 0.01) of 63.92 months
when comparing FGFR3high/Ki67high tumors (mean PFS: 54.87 months ± 6.73; 95% CI: 41.78 to 68.05)
with all other combinations (mean PFS: 118.78 months ± 6.95; 95% CI: 105.17 to 132.40). If, for example,
both markers were expressed at low levels, bladder cancer patients showed no progressive disease at
all (Figure S2A). Therefore, our results identify FGFR3high/Ki67high tumors as an aggressive subgroup.
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Figure 2. Prognostic impact of FGFR3 and Ki67 protein expression in all tumors (pTa, pT1 and pT2–4). 
Kaplan–Meier survival curves display progression-free survival (PFS). (A) Survival curves of patients 
with high FGFR3 expression (red curve, n = 56) compared to low FGFR3 expression (blue curve, n = 
30). (B) Kaplan–Meier analysis of patients with high Ki67 expression (red curve, n = 56) compared to 
low Ki67 expression (blue curve, n = 30). (C) Survival curve analysis of FGFR3high/Ki67high expression 
(red curve, n = 34) compared to all other combinations of FGFR3 and Ki67 expression (blue curve, n = 
32). n: overall number of cases; events: overall events of tumor progression. 
The calculated Cox regression model (including the potentially prognostic parameters stage, 
grade, age, keratin 20 and keratin 5/6) confirmed independency of the clinical impact of a 
FGFR3high/Ki67high status on progression-free survival. Patients displaying a combined overexpression 
of FGFR3 and Ki67 showed an approximately four-fold higher risk for tumor progression 
(multivariate hazard ratio (HR): 3.943, 95% CI: 1.247 to 12.466, p = 0.019) (Table 3). 
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Kaplan–Mei r survi al curves display progression-free survi al (PFS). (A) Survi al curves of patients
with igh FGFR3 expression (red curve, n = 56) compared to low FGFR3 expr ssion (blue curve, n = 30).
(B) Kaplan–Meier analysis of patients with high Ki67 expression (red curve, n = 56) compared to low
Ki67 expression (blue curve, n = 30). (C) Survival cur e analysis of FGFR3high/Ki67high expression (red
curve, n = 34) compared to all other combinations of FGFR3 and Ki67 expression (blue curve, n = 32).
n: overall number of cases; events: overall events of tumor progression.
The calculated Cox regression model (including the potentially prognostic parameters stage, grade,
age, keratin 20 and keratin 5/6) confirmed independency of the clinical impact of a FGFR3high/Ki67high
status on progression-free survival. Patients displaying a combined overexpression of FGFR3 and Ki67
showed an approximately four-fold higher risk for tumor progression (multivariate hazard ratio (HR):
3.943, 95% CI: 1.247 to 12.466, p = 0.019) (Table 3).
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Table 3. Multivariate Cox regression analysis of immunohistochemical markers including all factors
potentially influencing PFS.
Variable HR p-Value
95%CI
Lower Upper
FGFR3 high/Ki67high 3.943 0.019 1.247 12.466
pT status 0.957 0.941 0.295 3.105
Tumor grade 0.846 0.823 0.196 3.653
Keratin 5/6 0.482 0.280 0.128 1.812
Keratin 20 0.424 0.115 0.146 1.232
Age 1.773 0.347 0.537 5.847
2.2. Prognostic Impact of Ki67-Index and FGFR3 Overexpression in Papillary Non-Invasive (pTa) Tumors
Stratifying our cohort by invasiveness, i.e., into papillary non-invasive (pTa) and invasive tumors
(pT1–pT4), FGFR3 overexpression (Tomlinson Score 3) was not associated with tumor progression in
pTa bladder cancer (p > 0.05 for PFS) (Figure 3A).
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tumors. Kaplan–Mei r survival curves strate progression-free sur ival (PFS). (A) Survival
curves of patients with high FGFR3 expression (red curve, n = 39) compared to low FGFR3 expression
(blue curve, n = 11). (B) Kaplan–Meier analysis of patients with high Ki67 expression (red curve,
n = 28) compared to low Ki67 expression (blue curve, n = 22). (C) Impact of combined markers on risk
stratification of tumor progression is shown. Survival curve analysis of FGFR3high/Ki67high expression
(red curve, n = 20) compared to all other combinations of FGFR3 and Ki67 expression (blue curve,
n = 30) in pTa tumors. n, overall number of cases; events, overall events of tumor progression.
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Single marker analysis of high Ki67-index correlated with progression-free survival (∆mean
PFS: 17.06 months, p = 0.011) (Figure 3B). Now, combining the two immunohistochemical markers,
univariate Kaplan–Meier curve revealed a significant impact of FGFR3high/Ki67high expression on
patients’ outcome only in pTa tumors. In fact, patients with high FGFR3high/Ki67high showed a
significantly (p < 0.01) shorter progression-free survival (mean PFS: 55.89 months ± 9.23; 95% CI: 37.82
to 73.98) compared to those patients with all other combinations of FGFR3/Ki67 expression (mean
PFS: 113.85 months ± 8.12; 95% CI: 97.94 to 129.77, p = 0.009) (Figure 3C).
2.3. Altered Molecular FGFR3/TP53 Status Predicts Worse Patients’ Survival
Since we hypothesized that FGFR3-overexpression and high cell proliferation might indicate a
higher risk for progression in papillary non-invasive tumors, we further investigated the molecular
status of our cohort by studying both mutations for FGFR3 as papillary and TP53 as invasive markers
(for detailed mutation data, see Table S2). In total, 48 out of 99 (48.5%) analyzed patients harbored
mutations within the FGFR3 gene (Figure 4A).
The most frequent mutation was p.S249C (pTa: 13/21, pT1: 10/22, pT2–4: 2/5). FGFR3 mutations
showed no significant association with clinico-pathological parameters like tumor stage or grade
(Table S3). TP53 mutations were present in n = 23/98 (23.5%) patients (Figure 4A). There were
n = 18/23 (78.3%) tumors which solely showed missense mutations (pTa: 6/6, pT1: 7/11, pT2–4: 5/6)
and n = 5/23 (21.7%) tumors with mutations leading to a premature transcription stop either due to
the appearance of a stop codon or a frameshift (pTa: 0/6, pT1: 4/11, pT2–4: 1/6). TP53 mutations
correlated with tumor grade (p < 0.05) but not with stage (Table S4). Mutations in both genes (referred
to as double mutations) were found in n = 6/99 (6.1%) patients.
Survival analysis revealed no significant association between single mutations, i.e., FGFR3 or TP53,
with patient’s outcome for PFS (Figure 4B,C). However, mutations in both genes (FGFR3mut/TP53mut)
predicted unfavorable prognosis for PFS. Double mutations led to a reduced ∆mean PFS (p < 0.01) of
80.30 months: FGFR3mut/TP53mut tumors (mean PFS: 27.08 months ± 8.41; 95% CI: 10.59 to 43.57)
showed shorter PFS in contrast with all other combinations (mean PFS: 107.83 months ± 8.62; 95% CI:
90.49.17 to 124.28) (Figure 4D and Figure S2B).
Multivariate analysis confirmed the prognostic impact of FGFR3mut/TP53mut tumors.
Double mutated tumors exhibited a 6.6 times higher risk for tumor progression (multivariate hazard
ratio (HR): 6.563, 95% CI: 1.694 to 25.425, p = 0.006) (Table 4).
2.4. Prognostic Impact of FGFR3 and TP53 Mutations in Papillary Non-Invasive (pTa) Tumors
Next, we focused on pTa tumors, in particular those with FGFR3-overexpression and high cell
proliferation. In pTa tumors, the following distribution was found: n = 17/42 (40.5%) FGFR3wt/TP53wt,
n = 19/42 (45.2%) FGFR3mut/TP53wt, n = 4/42 (9.5%) FGFR3wt/TP53mut and n = 2/42 (4.8%)
FGFR3mut/TP53mut. On the contrary, pT1 tumors showed n = 9/39 (23.1%) FGFR3wt/TP53wt,
n = 19/39 (48.7%) FGFR3mut/TP53wt, n = 8/39 (20.5%) FGFR3wt/TP53mut and n = 3/39 (7.7%)
FGFR3mut/TP53mut. pT2–4 tumors represented with the following mutational pattern: n = 8/18
(44.4%) FGFR3wt/TP53wt, n = 4/18 (22.2%) FGFR3mut/TP53wt, n = 5/18 (27.8%) FGFR3wt/TP53mut
and n = 1/18 (5.6%) FGFR3mut/TP53mut.
Survival analyses revealed a correlation between FGFR3 mutations and shorter PFS (p = 0.041) in
pTa tumors (Figure 5A). TP53 mutations did not show any effects (p > 0.05) on PFS (Figure 5B).
Interestingly, tumors exhibiting double mutation status FGFR3mut/TP53mut (n = 6) presented a
dramatically reduced ∆mean PFS (p < 0.001) of 102.52 months (mean PFS: 5.00 months ± 1.00; 95% CI:
3.04 to 6.96) in pTa tumors (Figure 5C) compared with all other combinations (mean PFS: 107.52 months
± 9.72; 95% CI: 88.46 to 126.57).
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(A) Oncoprint graph for FGFR3 and TP53 mutation analysis. (B–D) Kaplan–Meier survival curves
display progr ssion-free survival (PFS). (B) Survival curves of tumors with detected FGFR3 mutations
(red curve, n = 30) compared to non-mutated FGFR3 gene status (blue curve, n = 34). (C) Kaplan–Meier
analysis of tumors with mutated TP53 (red curve, n = 17) compared to wildtype TP53 (blue curve,
n = 46). (D) Impact of double mutations on risk stratification of tumor progression is demonstrated.
Univariate analysis of double mutations (red curve, n = 6) compared to all other combinations of
mutated and non-mutated FGFR3 and TP53 genes (blue curve, n = 57). n, overall number of cases;
events, overall events of tumor progression.
Table 4. Multivariate Cox regression analysis of molecular markers including all factors potentially
influencing PFS.
Variable HR p-Value
95%CI
Lower Upper
FGFR3mut/TP53mut 6.563 0.006 1.694 25.425
pT status 1.179 0.821 0.284 4.896
Tumor grade 0.241 0.138 0.037 1.580
Keratin 5/6 0.714 0.621 0.188 2.712
Keratin 20 0.872 0.814 0.279 2.730
Age 1.41 0.584 0.412 2.809
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illustrates that detected FGFR3 mutations (red curve, n = 14) predict shorter PFS compared to
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Finally, we assessed the clinical impact of immunohistochemical and mutational status as a
combined approach. Survival analysis displayed that FGFR3mut/TP53mut double mutated tumors were
significantly associated with worse patients’ outcome only in FGFR3 and Ki67 overexpressing tumors:
reduced PFS in FGFR3high/Ki67high double mutated tumors compared with all other combinations
of molecular status of TP53 and FGFR3 (FGFR3wt/TP53wt p = 0.001; FGFR3mut/TP53wt p < 0.001;
FGFR3wt/TP53mut p = 0.116) (data not shown). However, it has to be noted that the number of double
mutations is very low, and, hence, statistical validity should be enhanced in future studies.
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2.5. FGFR3high/Ki67high Tumors Define a Subset of pTa Tumors Including Lesions with Molecular FGFR3
Pathway Activation
Prognostic stratification of bladder cancer patients in routine histopathological diagnostics claims
simple and cost-effective means, therefore, we evaluated the concordance of immunohistochemical
staining results and molecular status.
The majority of FGFR3high/Ki67high tumors was characterized by conjunct FGFR3 mutations with
a significant correlation only in papillary non-invasive tumors (pTa n = 19/27 (70.4%), p < 0.001) but not
in pT1 and pT2–4 tumors (Table S5). There was no significant correlation between FGFR3high/Ki67high
tumors and TP53 mutations independently of the given tumor stage (data not shown).
To evaluate the diagnostic potential of immunohistochemical markers covering the molecular
FGFR3 pathway, we performed ROC (Receiver operating characteristics) curve statistics to calculate
sensitivity and specificity. Accordingly, both immunohistochemical markers detect FGFR3 mutations
with 90.5% sensitivity and 61.9% specificity (area under curve (AUC): 0.776, p = 0.004, positive
predictive value (PPV): 70.4%, negative predictive value (NPV): 85.7%). These data show that
FGFR3high/Ki67high tumors include papillary lesions with mutation-based altered FGFR3 signaling, but
also tumors without molecular alterations (pTa n = 8/27 (29.6%)). Hence, our data give evidence that
FGFR3high/Ki67high tumors define a subset of pTa tumors associated with poor prognosis potentially
decoupled from the described protective effect of FGFR3 activation [7].
3. Discussion
In our study, we systematically analyzed papillary non-invasive and invasive tumors for
distinct prognostic immunohistochemical and molecular markers. We focused on a subgroup of
immunohistochemically FGFR3high/Ki67high tumors in order to reveal their prognostic impact on
patient survival and re-evaluate their histological classification/grading.
Although, according to nuclear and architectural criteria, these papillary tumors appear to be
orderly and more “nuclear low grade”, we found them associated with worse PFS compared with
FGFR3high/Ki67low tumors. This was especially evident in pTa tumors, where mean progression-free
survival was reduced to 55 instead of 113 months. Therefore, we asked whether these tumors harbor
a special molecular phenotype turning them into aggressive ones. In literature FGFR3 and TP53
mutations were initially thought to be mutually exclusive as FGFR3 mutations were associated with
pTa and LG tumors (“papillary pathway”), whereas the TP53 mutations were often found in invasive
and HG carcinomas (“CIS/invasive pathway”) [17,18]. Notwithstanding, Hernandez et al. reported
FGFR3 and TP53 mutations to be independently distributed in a large series of pT1G3 tumors, that
were consequently interpreted as a particular group of bladder tumors that could not be classified
into either one pathway or the other [4]. In our study, we saw a similar trend with well-known
inverse relationships between FGFR3 and TP53 mutations for both stage and grade, while mutations
in FGFR3 and TP53 revealed an independent but not mutually exclusive assignment (six tumors with
double mutations). Biologically activated FGFR3 signaling promotes cell proliferation and tumor
growth, however interestingly, highest numbers of FGFR3-alterations are found in benign papillary
or low grade papillary tumors with usually low proliferation (Ki67) index [19–21]. TP53 inactivation
results in reduced cellular apoptosis and thus maintains tumor growth via reduced cell death [22–25].
We hypothesized that a FGFR3high/Ki67high phenotype might be resulting from inactivated p53,
however we found no sufficient molecular evidence for this theory in our cohort. Recent comprehensive
sequencing data of papillary non-invasive bladder tumors revealed a genomic subtype 2, which is
characterized by loss of 9q (including TSC1), increased Ki67 labeling index, upregulated mTORC1
signaling, glycolysis, features of the unfolded protein response, altered cholesterol homeostasis and
DNA repair [15]. Therefore, high proliferation might be explained by mutations in DNA repair genes
or the deletion/mutation of TSC1, which consequently leads towards an upregulation of mTORC1
and PIK3CA mutations. Further analyses to strengthen this theory have to be performed in the future.
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Comprehensive molecular data of bladder cancer has been gained in the recent years [15,26,27],
however, complex multigene analysis and RNA expression analysis are costly and laborious, and
therefore cost-effective simple analyses for routine histological examination are needed. In our study,
we analyzed whether fast and simple immunohistochemical analyses are suitable to detect a more
aggressive molecular subtype. We found a highly significant correlation between strong FGFR3/Ki67
immunohistochemical staining and FGFR3 mutation status, which indicates that FGFR3 protein
expression is more frequent than mutational activation [16]. Moreover, our FGFR3high/Ki67high
subgroup also comprises those neoplasms without any molecular (FGFR3 and/or TP53) alterations
defining in this combination a subset of pTa tumors with poor prognosis, i.e., FGFR3 overexpression
was associated with unfavorable outcome as previously shown, for instance, for invasive bladder
tumors treated with adjuvant chemotherapy [28]. Thus, our data support the proposed clinical
significance of these two immunohistochemical markers for diagnostic and prognostic stratification of
more aggressive papillary non-invasive bladder tumors.
Taken together, we found immunohistochemically FGFR3high/Ki67high pTa tumors associated
with worse prognosis/survival, despite appearing histologically of “lower nuclear grade”/G2. Even if
these tumors appear to be “low grade” (according to the 2004 WHO classification), we recommend
classifying them as “high grade” pTa tumors. In light of our findings, we suggest immunohistochemical
staining for FGFR3 and Ki67 in order to gain evidence for this more aggressive molecular subgroup with
worse prognosis. These patients probably could profit from close endoscopic follow-up, as especially
urine cytology might also be challenging/less sensitive due to their minimal nuclear changes.
4. Materials and Methods
4.1. Patient Samples, Tissue Microarrays and DNA
We retrospectively selected urothelial bladder cancer cases (mutational analysis: n = 42 pTa, n
= 39 pT1, n = 18 pT2–4; immunohistochemical analysis: n = 82 pTa, n = 42 pT1, n = 18 pT2–4) from
our pathology archive and from the archive of the Institute of Pathology in Erlangen. Formalin-fixed
paraffin-embedded (FFPE) surgical specimens were used to construct tissue microarrays (all samples)
and extract DNA (n = 99 samples) using Qiagen kits (Qiagen, Hilden, Germany) as previously
described [29–31]. Patient information was obtained by the Department of Urology and the local ethics
committee approved a retrospective, pseudonymized study of archival tissues (RWTH EK 009/12).
Histological tumor grade and stage was classified according to WHO 2004 classification [8].
4.2. Immunohistochemistry
For immunohistochemical stainings, TMA sections were pretreated with DAKO PT-Link heat
induced antigen retrieval with Low pH (pH 6) or High pH (pH 9) Target Retrieval Solution (DAKO,
Hamburg, Germany) and incubated for 30 min at room temperature with respective antibodies
in a DAKO Autostainer (DAKO). For stainings anti-FGFR3 (clone B9, PTlink pH6, dilution 1:25,
Flex+M; Santa Cruz Biotechnology, Heidelberg, Germany), anti-Ki67 (clone MIB-1, PTlink pH 6,
dilution 1:400, Flex+M; DAKO), anti-CK 20 (clone Ks20.8, PTlink pH 6, dilution 1:200, Flex+M;
DAKO), and anti-CK5/6 (clone D5/16 B4, PTlink pH 9, dilution 1:100, Flex+M; DAKO) were used.
Appropriate linker molecules EnVisionTMFLEX+ (mouse/rabbit), EnVision FLEX/HRP detection
system and counterstaining with EnVision FLEX Hematoxylin were applied. Stainings were evaluated
by an experienced uropathologist (NTG) who was blinded for patient identity, diagnosis and clinical
follow-up results. FGFR3 positivity was reported according to a semiquantitative scoring system
developed by Tomlinson et al. [16]. All other stainings were evaluated for staining intensities (0 = no
staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining) and percentages of positive
stained tumor cells. Results were judged as follows: Keratin 20 positive ≥10% stained cells [14,32],
Keratin 5/6 positive ≥10% [32], Ki67 positive ≥15% [11,13] stained cells.
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4.3. Fluorescence In Situ Hybridization
ZytoLight Dual Color Probe SPEC FGFR3/CEN 4 and ZytoLight Dual Color Break Apart Probe
SPEC FGFR3 (Zytovision, Bremerhaven, Germany) were hybridized onto 3 µm TMA sections according
to the manufacturer’s protocols. Slides were evaluated with a Zeiss Axiovert 135 fluorescence
microscope (Carl Zeiss, Oberkochen, Germany), and Diskus Software (MIL 7.5, 4.80) (Büro Hilgers,
Königswinter, Germany) using appropriate channels/filters (AHF ZyGreen F36-720, AHF ZyOrange
F36-740, AHF DAPI, AHF F56-700). Signals of 60 nuclei of tumor cells were counted at high
magnification (×1000) and judged as described previously [33].
4.4. Sanger Sequencing
PCR-amplification of exons 7, 10 and 15 of the FGFR3 gene and exons 5, 6, 7, 8 and 9 of TP53
were carried out using routine protocols. Primers and annealing temperatures are given in Table S6.
PCR products were purified by either ExoSAP-IT (Affymetrix, Lahr/Schwarzwald, Germany) or a
PCR purification kit (PerkinElmer Chemagen, Baesweiler, Germany) according to the manufacturer’s
instructions. Sanger sequencing of both strands was run on an ABI PRISM 3500 Genetic Analyzer
(Applied Biosystems, Weiterstadt, Germany) using the Big dye Terminator kit (Applied Biosystems),
the same primer sets and the seq purification kit (PerkinElmer Chemagen).
4.5. Statistical Analysis
Statistical analysis was performed using SPSS (Statistical Package for the Social Sciences)
software version 23.0 (SPSS Inc., Chicago, IL, USA). p-values < 0.05 were considered significant.
Statistical associations between clinico-pathological and molecular factors were determined by
Fisher’s exact test. Correlation analysis was performed by calculating a Spearman’s rank correlation
coefficient. Survival (progression-free survival (PFS)) was calculated using the Kaplan–Meier
method with log-rank statistics. Survival was measured from surgery until relapse, death or
progression and was censored for patients alive without evidence of event at the last follow-up
date. Multivariate Cox-regression analysis was performed to test for an independently prognostic
value of FGFR3-Ki67 protein expression and FGFR3-TP53 mutations. Receiver operating characteristics
(ROC) curves were calculated to assess biomarker performance of immunohistochemical markers
regarding molecular alterations.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/9/
2548/s1.
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